Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Is up Today While the Market Is Down

By Eric Volkman – Updated Sep 30, 2021 at 5:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is building a new research and development center.

What happened

Moderna (MRNA 3.15%) was having a healthy Thursday on the market. The coronavirus vaccine stock was up by 1.5% in late afternoon trading following the announcement of a new company facility, and on the back of generally favorable developments in the fight against COVID-19.

So what

Moderna said that it is investing in the facility, to be known as the Moderna Science Center and located near the company's headquarters in Cambridge, Massachusetts. It described the Moderna Science Center as "a purpose-built space to support the Company's next chapter of discovery," as it furthers its research into mRNA-based products such as the mRNA-1273 coronavirus vaccine that's in wide circulation.

Gloved hand filling a syringe from a vial.

Image source: Getty Images.

Construction of the 462,000-square-foot facility has begun, the biotech added, and move-in is expected to begin in 2023. The company did not specify how much it was investing into the Center.

Meanwhile, Tuesday's coronavirus vaccination news was positive, for the most part. The Los Angeles city council is considering an ordinance that would mandate customers of a wide range of businesses (gyms, movie theaters, etc.) show proof of vaccination for entry. This should coax vaccine holdouts in America's second-largest city to finally get their jabs; perhaps it will lead to similar citywide mandates elsewhere.

Also, The New York Times is reporting that Asian countries are significantly ramping up their vaccination programs. While the Moderna vaccine isn't as much of a go-to there as in Western nations, it is authorized for use in countries such as Singapore.

Now what

We are approaching the one-year anniversary of Moderna's shot receiving its Emergency Use Authorization (EUA) from the FDA. The jab remains one of the most effective weapons in the war against the coronavirus. As long as COVID is spreading, the shot and its maker will remain relevant...and very much on the radar of investors.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Stocks Mentioned

Moderna Stock Quote
$179.00 (3.15%) $5.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.